Verve Therapeutics aims to revolutionize cardiovascular disease treatment with single-course gene editing. Click here to read ...
Viking Therapeutics' financial stability supports its ongoing and future clinical trials, making it a viable long-term ...
Eli Lilly said on Tuesday it has begun selling vials of the lowest starter dose of its popular weight-loss drug Zepbound in the United States for $399 for a month's supply through its ...
Eli Lilly will begin offering its popular new weight-loss drug Zepbound in vials—in addition to standard injection-pen devices—at about half the price of the original for certain doses.
Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand ...
Aug 27 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday it has begun selling vials of the lowest starter dose of its popular weight-loss drug Zepbound in the United States for $399 for ...
Patients with a prescription for Zepbound can purchase a month’s supply of single-use vials through Lilly’s direct-to-consumer site starting Tuesday, the company said in a statement. The vials ...
Now, Eli Lilly is looking to lower that cost a little. At baseline, this version of Zepbound is the same—meaning, it’s still tirzepatide, which is a FDA-approved medication to help with weight ...
Eli Lilly has cut the prices of its two lowest doses of weight-loss drug Zepbound by releasing them as single-dose vials, the pharmaceutical company announced Tuesday. Eli Lilly said the two ...
Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound, it said Tuesday, in a move to expand access and ease supply constraints.
Eli Lilly is launching singe-use vials of its popular weight-loss drug Zepbound, which will be half the price of previous versions of the drug. The traditional injector pens are more difficult to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results